查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004656

乳癌液态生物检体设备市场：按技术、检测类型、检体类型、适应症、应用和最终用户划分——2026-2032年全球市场预测

Breast Cancer Liquid Biopsy Testing Devices Market by Technology, Test Type, Sample Type, Indication, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，乳癌液态生物检体设备市场价值将达到 12.3 亿美元，到 2026 年将成长至 14.5 亿美元，到 2032 年将达到 44.6 亿美元，复合年增长率为 20.13%。

主要市场统计数据
基准年 2025 12.3亿美元
预计年份：2026年 14.5亿美元
预测年份 2032 44.6亿美元
复合年增长率 (%) 20.13%

重点关注液态生物检体在乳癌治疗和创新路径中不断变化的作用。

液态生物检体技术已从小众研究工具发展成为精准肿瘤学的关键组成部分，为检测肿瘤来源的生物标记提供了微创的组织切片检查替代方案。随着临床团队寻求更快、更安全、更可重复的肿瘤动态监测方法，液态生物检体检测设备为改善早期检测、指南治疗方法选择和追踪微小残留病灶提供了机会。本文首先阐明循环肿瘤DNA、循环性肿瘤细胞和细胞外囊泡（如外泌体）的科学基础，并解释检测的敏感度、特异性和通量如何影响其临床应用，从而奠定了微量残存疾病技术的基础。

变革性的变化正在重塑乳癌液态生物检体。

液态生物检体诊断设备领域正经历快速变革，这主要得益于检测化学、仪器灵敏度和生物资讯技术的进步。用于检测低频突变的高解析度技术以及结合ctDNA、CTC和外泌体成分的多参数分析方法，正在拓展其临床应用。同时，检体处理和标准化的进步降低了分析前的变异性，从而实现了更可靠的时间序列监测。这些技术进步，加上临床指引的不断发展（这些指引日益重视微创诊断在治疗方法选择和疾病后续观察评估中的价值），进一步提升了液体切片的价值。

评估 2025 年美国关税变化对诊断设备製造商的供应链、成本和策略采购的累积影响。

美国近期关税调整对整个医疗设备供应链产生了影响，促使诊断设备製造商重新评估筹资策略和成本结构。微流体晶片、特殊聚合物和半导体光学元件等对数位PCR和定序设备至关重要的组件可能面临更高的运输成本，迫使供应商考虑近岸外包、双重采购或重新设计组件等替代方案。对于垂直整合试剂和耗材的供应商而言，关税带来的价格压力可能会影响利润率，并加速与契约製造就长期供应合约进行谈判。

深入了解关键细分市场，揭示技术选择、应用、使用者环境、测试方法、检体工作流程、临床适应症和通路。

細項分析揭示了创新和应用集中在哪些领域，以及某些平台在特定应用场景中广受欢迎的原因。技术细分比较了数位PCR、次世代定序和即时PCR。数位PCR进一步分为晶片式和液滴式数位PCR；次世代定序分为标靶定序、全EXOME定序和全基因测序；即时PCR分为染料法和探针法。这些差异会影响分析灵敏度、多重检测能力和单次检测成本，进而影响临床应用率。

关键区域见解解释了主要区域的部署趋势、医疗保健系统优先事项和法规结构有何不同，以及它们如何影响部署策略。

区域趋势影响液态生物检体检测设备在肿瘤治疗路径中的应用、报销和整合。在美洲，由于分散式检查基础设施和蓬勃发展的私人实验室产业，临床网路和学术机构通常主导初步的临床检验和应用。相较之下，欧洲、中东和非洲（EMEA）地区的格局更为复杂，监管协调和公共报销框架的完善影响着液体活检设备的普及，而集中式标准实验室则与医疗保险机构合作，以证明其健康经济价值。在亚太地区，基因组基础设施的快速投资、不断扩大的临床试验活动以及多样化的公私合营医疗模式，为集中式和照护现场（POC​​）解决方案创造了机会。

主要企业洞察整合了竞争性提案、差异化策略和合作模式，从而塑造了诊断开发公司的竞争格局。

领先的诊断公司和新兴的专业公司正在采取互补策略来实现产品差异化。一些公司专注于平台层面的整合，将高灵敏度仪器、专有试剂和云端分析功能结合，建构强大的生态系统，从而锁定实验室客户。另一些公司则专注于特定的临床适应症和检体类型，优化检测方法的化学特性，以用于早期检测和微量残存疾病监测，在这些领域，超高的灵敏度和特异性至关重要。受託研究机构(CRO) 和临床实验室也发挥关键作用，在监管部门核准之前，为新型检测方法提供检验流程和规模化生产能力。

为旨在扩大临床应用、优化产品市场契合度并维持液态生物检体检测竞争优势的行业领导者提供实用建议。

为了将科学进步转化为商业性成功，产业领导者应优先考虑创建与特定临床应用案例相符的策略证据。这包括设计能够证明产品在早期检测、復发检测或治疗监测方面具有临床附加价值的研究，并在临床路径开发的早期阶段就与关键意见领袖进行沟通。同时，应投资稳健的样本製备流程以及与实验室资讯系统的互通性，以最大限度地减少医院检查室和参考中心采用该产品的障碍。此外，製造商应探索混合商业化模式，将面向客户的高触感达直销与透过线上通路和经销商开展的合作相结合，以扩大其市场覆盖范围。

本报告描述了调查方法，包括跨学科方法、资料三角测量和检验程序，这些都构成了所提出的研究结果和见解的基础。

本调查方法整合了技术文献综述、监管和政策分析以及结构化的相关人员对话，以确保观点平衡且实用。主要资讯来源包括对临床专业人员、实验室经理、采购经理和行业高管的访谈，以了解实际操作、推广应用障碍和商业化策略。二级资讯来源包括同行评审文章、会议论文集以及公开的监管文件和指导文件，这些资料构成了检测性能和临床效用技术说明的基础。

总结了下一阶段临床和商业开发的机会领域、当前挑战和策略重点。

液态生物检体设备在技术、临床需求和医疗保健系统优先事项的交汇点占据着至关重要的地位。非侵入性检测肿瘤讯号的能力不断增强，为改善早期检测、优化预后和加强治疗监测提供了实际的机会。然而，要实现这些机会，需要解决技术差异性问题，使证据产生与支付方的期望相符，并确保工作流程与临床检查室操作无缝衔接。目前面临的挑战包括：标准化样本製备流程、证明疗效的显着改善，以及建立能够反映诊断价值的永续报销机制。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章乳癌液态生物检体设备市场：依技术划分

  • 数位PCR
    • 基于晶片的数位PCR
    • 液滴式数位PCR
  • 次世代定序
    • 目标序列
    • 全EXOME定序
    • 全基因组定序
  • 即时PCR
    • 基于染料的PCR
    • 基于探针的PCR

第九章：乳癌液态生物检体设备市场（依检测类型划分）

  • 用于体外诊断
    • 装置
    • 试剂
  • 实验室开发的测试
    • 基于NGS的LDT
    • 基于PCR的LDT

第十章检体类型分類的乳癌液态生物检体设备市场

  • 电浆
  • 血清
  • 全血

第十一章乳癌液态生物检体设备市场：依适应症划分

  • 早期检测
  • 预后
  • 復发检测
  • 治疗监测

第十二章乳癌液态生物检体设备市场：依应用领域划分

  • 循环性肿瘤细胞
  • 循环肿瘤DNA
  • 外泌体
    • 外泌体DNA
    • 外泌体RNA

第十三章乳癌液态生物检体设备市场：依最终用户划分

  • 合约研究机构
  • 诊断检测实验室
  • 医院和诊所
  • 研究机构

第十四章乳癌液态生物检体设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章乳癌液态生物检体设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章乳癌液态生物检体设备市场：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国乳癌液态生物检体设备市场

第十八章：中国乳癌液态生物检体设备市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Angle plc
  • Biocept Inc.
  • Cynvenio Biosystems Inc.
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Fluxion Biosciences Inc.
  • GRAIL LLC
  • Guardant Health Inc.
  • Illumina Inc.
  • Inivata Ltd.
  • Lucence Health Pte Ltd
  • Menarini Silicon Biosystems
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories
  • Personal Genome Diagnostics Inc.
  • Predicine Inc.
  • Qiagen NV
  • Resolution Bioscience Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trovagene Inc.
  • Vortex Biosciences
Product Code: MRR-742BD517C0D8

The Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 1.23 billion in 2025 and is projected to grow to USD 1.45 billion in 2026, with a CAGR of 20.13%, reaching USD 4.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.23 billion
Estimated Year [2026] USD 1.45 billion
Forecast Year [2032] USD 4.46 billion
CAGR (%) 20.13%

A focused introduction to the evolving role of liquid biopsy testing in breast cancer care and innovation pathways

Liquid biopsy technologies have moved from niche research tools to pivotal components of precision oncology, offering minimally invasive alternatives to tissue biopsies for detecting tumor-derived biomarkers. As clinical teams seek faster, safer, and more repeatable modalities to monitor tumor dynamics, liquid biopsy testing devices present opportunities to improve early detection, guide therapeutic selection, and track minimal residual disease. This introduction sets the stage by clarifying the scientific underpinnings-circulating tumor DNA, circulating tumor cells, and extracellular vesicles such as exosomes-and by describing how assay sensitivity, specificity, and throughput shape clinical applicability.

Transitioning from bench to bedside requires alignment across assay platforms, sample handling protocols, and data interpretation frameworks. Regulatory pathways and reimbursement considerations further influence adoption timelines, while vendor investments in assay validation, automation, and interoperability determine competitive positioning. Ultimately, stakeholders must balance technical performance with workflow compatibility, cost-efficiency, and clinical utility to realize the promise of liquid biopsy testing devices in routine breast cancer management.

Transformative shifts reshaping technology, clinical practice, and commercialization in breast cancer liquid biopsy testing

The landscape of liquid biopsy testing devices has undergone rapid transformation driven by advances in assay chemistry, instrument sensitivity, and bioinformatics. High-resolution techniques that detect low-frequency variants and multi-analyte approaches combining ctDNA, CTCs, and exosomal content are expanding clinical use cases. Concurrently, improvements in sample processing and standardization have reduced pre-analytical variability, enabling more reliable longitudinal monitoring. These technical gains are complemented by evolving clinical guidelines that increasingly recognize the value of minimally invasive diagnostics for treatment selection and disease surveillance.

On the commercialization front, strategic collaborations between diagnostic developers, clinical laboratories, and oncology centers are accelerating evidence generation and real-world validation. Partners are prioritizing scalable workflows and cloud-enabled analytics to support decentralized testing and remote monitoring. Moreover, payer dialogue has shifted toward value-based reimbursement for diagnostics that demonstrably improve outcomes or reduce downstream costs. Taken together, these shifts create a convergence of scientific maturity and commercial readiness that is changing how clinicians and health systems approach breast cancer detection and management.

Assessing the cumulative impact of United States tariff changes in 2025 on supply chains, costs, and strategic sourcing for diagnostic device manufacturers

Recent tariff adjustments in the United States have reverberated across medical device supply chains, prompting diagnostic manufacturers to reassess sourcing strategies and cost structures. Components such as microfluidic chips, specialty polymers, and semiconductor-based optics that are integral to digital PCR and sequencing instruments may face higher landed costs, compelling vendors to evaluate nearshoring, dual sourcing, or redesign for component substitution. For vertically integrated suppliers of reagents and consumables, tariff-induced price pressure can affect margin profiles and may accelerate negotiations with contract manufacturers to secure long-term supply agreements.

In response to these pressures, some organizations are intensifying supplier qualification and inventory management practices while accelerating investments in local manufacturing capabilities to mitigate exposure. Regulatory and logistics teams are also collaborating more closely to ensure continuity of reagent supply and to minimize disruptions to clinical testing services. As a result, procurement decisions increasingly weigh not only unit cost but also supply resilience, lead times, and inventory carrying implications, shaping longer-term strategic planning across the diagnostic ecosystem.

Key segmentation insights that illuminate technological choices, applications, user environments, testing approaches, specimen workflows, clinical indications, and distribution pathways

Segmentation analysis clarifies where innovation and adoption are concentrated and why certain platforms gain traction in specific use cases. Technology segmentation compares digital PCR, next generation sequencing, and real time PCR, with digital PCR further differentiated into chip based and droplet digital formats, next generation sequencing spanning targeted sequencing, whole exome sequencing, and whole genome sequencing, and real time PCR evaluated across dye based and probe based chemistries. These distinctions matter for analytical sensitivity, multiplexing capacity, and cost per assay, which in turn influence clinical uptake.

Application segmentation assesses circulating tumor cells, circulating tumor DNA, and exosomes, with exosomes further disaggregated into exosomal DNA and exosomal RNA; each analyte class offers distinct biological insight and requires tailored extraction and analysis workflows. End user segmentation highlights contract research organizations, diagnostic laboratories, hospitals and clinics, and research centers as primary adopters, with differing demands for throughput, turnaround time, and regulatory compliance. Test type segmentation contrasts in vitro diagnostic instruments and reagents against laboratory developed tests, noting that in vitro diagnostics split into instrument and reagent categories while laboratory developed tests are often grouped as NGS based LDTs and PCR based LDTs, each with unique validation and commercialization pathways.

Sample type segmentation examines plasma, serum, and whole blood as critical pre-analytical variables that affect yield and assay performance. Indication segmentation differentiates early detection, prognosis, recurrence detection, and treatment monitoring as distinct clinical endpoints that drive assay selection and evidence generation. Finally, distribution channel segmentation contrasts direct sales, online sales, and third party distributors, recognizing that online sales may occur via e-commerce platforms or manufacturer websites, which impacts channel strategy, pricing, and customer support. Integrating these segmentation perspectives reveals where vendors should concentrate R&D, regulatory efforts, and commercial resources to align product features with end-user needs and clinical value.

Key regional insights that explain how adoption dynamics, health system priorities, and regulatory frameworks vary across major global regions and influence deployment strategies

Regional dynamics shape how liquid biopsy testing devices are adopted, reimbursed, and integrated with oncology pathways. In the Americas, clinical networks and academic centers often drive early clinical validation and adoption, supported by infrastructure for decentralized testing and an active private laboratory sector. Meanwhile, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts and public reimbursement frameworks influence uptake, and where centralized reference laboratories collaborate with healthcare payers to demonstrate health economic value. In Asia-Pacific, rapid investments in genomics infrastructure, expanding clinical trial activity, and diverse public-private healthcare models create opportunities for both centralized and point-of-care solutions.

These regional differences affect product design, from instrument footprint and reagent cold-chain requirements to language localization and integration with electronic health records. Market entry strategies must therefore be tailored: some regions prioritize extensive clinical utility data and health technology assessments, whereas others emphasize cost-efficiency and scalable deployment. Strategic partnerships with regional laboratory networks, key opinion leaders, and local regulatory experts are essential to accelerate clinical adoption and to navigate payer negotiations across these varied geographies.

Key company insights that synthesize competitive offers, differentiation strategies, and collaboration patterns shaping the competitive landscape for diagnostic developers

Leading diagnostic companies and emerging specialists are pursuing complementary approaches to differentiate their offerings. Some firms emphasize platform-level integration-pairing high-sensitivity instruments with proprietary reagents and cloud-based analytics-to create defensible ecosystems that lock in laboratory customers. Other organizations focus on niche clinical indications or specimen types, optimizing assay chemistry for early detection or minimal residual disease monitoring where ultra-high sensitivity and specificity are prerequisites. Contract research organizations and clinical service laboratories also play a critical role, providing validation pipelines and scaling capabilities for novel assays prior to regulatory clearance.

Partnerships between technology providers, academic centers, and oncology networks have become a primary vehicle for generating clinical evidence and accelerating guideline inclusion. Strategic M&A activity and licensing agreements continue to reconfigure capability stacks, enabling some vendors to bridge gaps in bioinformatics, sample processing, or global distribution. For decision-makers, choosing partners and suppliers involves balancing technical merit, evidence generation capacity, and commercialization reach to achieve durable clinical and commercial outcomes.

Actionable recommendations for industry leaders aiming to scale clinical adoption, optimize product-market fit, and sustain competitive advantage in liquid biopsy testing

To translate scientific advances into commercial success, industry leaders should prioritize strategic evidence generation that aligns with specific clinical use cases. Design studies that demonstrate incremental clinical value in early detection, recurrence detection, or therapy monitoring, and engage key opinion leaders early to shape clinical pathways. In parallel, invest in robust pre-analytical workflows and interoperability with laboratory information systems to minimize barriers to adoption among hospital laboratories and reference centers. Manufacturers should also evaluate hybrid commercialization approaches that combine direct sales for high-touch accounts with online channels and distributor relationships to broaden reach.

Operationally, strengthening supply chain resilience through diversified sourcing, local manufacturing options, or longer-term supplier agreements will reduce exposure to tariff and logistics risks. From a product perspective, prioritize modularity and software-enabled upgrades so instruments can evolve with bioinformatic advances without requiring full hardware replacement. Finally, pursue payer engagement strategies that frame diagnostics as value drivers, collaborating on outcomes studies and real-world evidence generation to support reimbursement conversations and long-term adoption.

Research methodology that explains the multidisciplinary approach, data triangulation, and validation steps underpinning the report's findings and insights

The research methodology integrates technical literature review, regulatory and policy analysis, and structured stakeholder engagement to ensure a balanced and actionable perspective. Primary inputs include interviews with clinical experts, laboratory directors, procurement leads, and industry executives to capture operational realities, adoption barriers, and commercialization strategies. Secondary sources span peer-reviewed publications, conference proceedings, and publicly available regulatory filings and guidance documents to ground technical statements about assay performance and clinical utility.

Analysts conducted a rigorous triangulation process to cross-validate findings, reconciling interview insights with published evidence and product specifications. Where possible, methodological transparency was maintained by documenting inclusion criteria for studies, the scope of stakeholder interviews, and the rationale for interpreting clinical endpoints. This approach ensures that conclusions reflect both the latest scientific understanding and real-world constraints that influence implementation and scale-up of liquid biopsy testing devices.

Concluding synthesis that encapsulates opportunity areas, persistent challenges, and strategic priorities for the next phase of clinical and commercial development

Liquid biopsy testing devices occupy a pivotal intersection of technology, clinical need, and health system priorities. The growing capability to detect tumor-derived signals noninvasively presents tangible opportunities to improve early detection, refine prognosis, and enhance treatment monitoring. Nonetheless, realization of these opportunities hinges on addressing technical variability, aligning evidence generation with payer expectations, and ensuring that workflows integrate seamlessly with clinical laboratory operations. Persistent challenges include harmonizing pre-analytical practices, demonstrating clear outcome improvements, and creating sustainable reimbursement pathways that reflect the diagnostic's value contribution.

Looking ahead, stakeholders who combine rigorous clinical validation, pragmatic product design, and strategic partnerships will be best positioned to translate assays into widely adopted clinical tools. Emphasizing modular platforms, resilient supply chains, and engagement with regulatory and payer ecosystems will accelerate adoption. In sum, the next phase requires coordinated action across developers, clinicians, laboratories, and health systems to transform promising technologies into routine components of breast cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Liquid Biopsy Testing Devices Market, by Technology

  • 8.1. Digital PCR
    • 8.1.1. Chip Based Digital PCR
    • 8.1.2. Droplet Digital PCR
  • 8.2. Next Generation Sequencing
    • 8.2.1. Targeted Sequencing
    • 8.2.2. Whole Exome Sequencing
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Real Time PCR
    • 8.3.1. Dye Based PCR
    • 8.3.2. Probe Based PCR

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Test Type

  • 9.1. In Vitro Diagnostic
    • 9.1.1. Instruments
    • 9.1.2. Reagents
  • 9.2. Laboratory Developed Test
    • 9.2.1. NGS Based LDT
    • 9.2.2. PCR Based LDT

10. Breast Cancer Liquid Biopsy Testing Devices Market, by Sample Type

  • 10.1. Plasma
  • 10.2. Serum
  • 10.3. Whole Blood

11. Breast Cancer Liquid Biopsy Testing Devices Market, by Indication

  • 11.1. Early Detection
  • 11.2. Prognosis
  • 11.3. Recurrence Detection
  • 11.4. Treatment Monitoring

12. Breast Cancer Liquid Biopsy Testing Devices Market, by Application

  • 12.1. Circulating Tumor Cells
  • 12.2. Circulating Tumor DNA
  • 12.3. Exosomes
    • 12.3.1. Exosomal DNA
    • 12.3.2. Exosomal RNA

13. Breast Cancer Liquid Biopsy Testing Devices Market, by End User

  • 13.1. Contract Research Organizations
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals And Clinics
  • 13.4. Research Centers

14. Breast Cancer Liquid Biopsy Testing Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Breast Cancer Liquid Biopsy Testing Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Breast Cancer Liquid Biopsy Testing Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Breast Cancer Liquid Biopsy Testing Devices Market

18. China Breast Cancer Liquid Biopsy Testing Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Angle plc
  • 19.7. Biocept Inc.
  • 19.8. Cynvenio Biosystems Inc.
  • 19.9. Epic Sciences Inc.
  • 19.10. Exact Sciences Corporation
  • 19.11. F. Hoffmann-La Roche Ltd
  • 19.12. Fluxion Biosciences Inc.
  • 19.13. GRAIL LLC
  • 19.14. Guardant Health Inc.
  • 19.15. Illumina Inc.
  • 19.16. Inivata Ltd.
  • 19.17. Lucence Health Pte Ltd
  • 19.18. Menarini Silicon Biosystems
  • 19.19. Myriad Genetics Inc.
  • 19.20. NeoGenomics Laboratories
  • 19.21. Personal Genome Diagnostics Inc.
  • 19.22. Predicine Inc.
  • 19.23. Qiagen N.V.
  • 19.24. Resolution Bioscience Inc.
  • 19.25. Sysmex Corporation
  • 19.26. Thermo Fisher Scientific Inc.
  • 19.27. Trovagene Inc.
  • 19.28. Vortex Biosciences

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES